Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21219881rdf:typepubmed:Citationlld:pubmed
pubmed-article:21219881lifeskim:mentionsumls-concept:C0023493lld:lifeskim
pubmed-article:21219881lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:21219881lifeskim:mentionsumls-concept:C1414349lld:lifeskim
pubmed-article:21219881lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:21219881lifeskim:mentionsumls-concept:C1721586lld:lifeskim
pubmed-article:21219881pubmed:issue6lld:pubmed
pubmed-article:21219881pubmed:dateCreated2011-2-21lld:pubmed
pubmed-article:21219881pubmed:abstractTextWe evaluated the anti-adult T-cell leukemia (ATL) effects of hippuristanol, an eukaryotic translation initiation inhibitor from the coral Isis hippuris. Hippuristanol inhibited proliferation of HTLV-1-infected T-cell lines and ATL cells, but not normal peripheral blood mononuclear cells. It induced cell cycle arrest during G? phase by reducing the expression of cyclin D1, cyclin D2, CDK4 and CDK6, and induced apoptosis by reducing the expression of Bcl-x(L), c-IAP2, XIAP and c-FLIP. The induced apoptosis was associated with activation of caspase-3, -8 and -9. Hippuristanol also suppressed IkappaBalpha phosphorylation and depleted IKKalpha, IKKgamma, JunB and JunD, resulting in inactivation of NF-kappaB and AP-1. It also suppressed carbonic anhydrase type II expression. In addition to its in vitro effects, hippuristanol suppressed tumor growth in mice with severe combined immunodeficiency harboring tumors induced by inoculation of HTLV-1-infected T cells. These preclinical data suggest that hippuristanol could be a potentially useful therapeutic agent for patients with ATL.lld:pubmed
pubmed-article:21219881pubmed:languageenglld:pubmed
pubmed-article:21219881pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21219881pubmed:citationSubsetIMlld:pubmed
pubmed-article:21219881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21219881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21219881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21219881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21219881pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21219881pubmed:statusMEDLINElld:pubmed
pubmed-article:21219881pubmed:monthMarlld:pubmed
pubmed-article:21219881pubmed:issn1873-2968lld:pubmed
pubmed-article:21219881pubmed:authorpubmed-author:MoriNaokiNlld:pubmed
pubmed-article:21219881pubmed:authorpubmed-author:SenbaMasachik...lld:pubmed
pubmed-article:21219881pubmed:authorpubmed-author:TanakaJunichi...lld:pubmed
pubmed-article:21219881pubmed:authorpubmed-author:IshikawaChieClld:pubmed
pubmed-article:21219881pubmed:authorpubmed-author:NakachiSawako...lld:pubmed
pubmed-article:21219881pubmed:authorpubmed-author:MachijimaYosh...lld:pubmed
pubmed-article:21219881pubmed:authorpubmed-author:TsumurayaTomo...lld:pubmed
pubmed-article:21219881pubmed:copyrightInfoCopyright © 2011 Elsevier Inc. All rights reserved.lld:pubmed
pubmed-article:21219881pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21219881pubmed:day15lld:pubmed
pubmed-article:21219881pubmed:volume81lld:pubmed
pubmed-article:21219881pubmed:ownerNLMlld:pubmed
pubmed-article:21219881pubmed:authorsCompleteYlld:pubmed
pubmed-article:21219881pubmed:pagination713-22lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:meshHeadingpubmed-meshheading:21219881...lld:pubmed
pubmed-article:21219881pubmed:year2011lld:pubmed
pubmed-article:21219881pubmed:articleTitleEffects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia.lld:pubmed
pubmed-article:21219881pubmed:affiliationDepartment of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan.lld:pubmed
pubmed-article:21219881pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21219881pubmed:publicationTypeComparative Studylld:pubmed